- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04861259
A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS) (COMMUTE-a)
A Phase III, Multicenter, Single-Arm Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Adult and Adolescent Patients With Atypical Hemolytic Uremic Syndrome (aHUS)
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Reference Study ID Number: BO42353 https://forpatients.roche.com/
- Phone Number: 888-662-6728 (U.S. and Canada)
- Email: global-roche-genentech-trials@gene.com
Study Locations
-
-
-
Leuven, Belgium, 3000
- Recruiting
- UZ Leuven Gasthuisberg
-
-
-
-
MG
-
Belo Horizonte, MG, Brazil, 30150-221
- Active, not recruiting
- Santa Casa de Misericordia; de Belo Horizonte
-
-
SP
-
Botucatu, SP, Brazil, 18618-686
- Active, not recruiting
- UPECLIN Hospital das Clinicas da Faculdade de Medicina de Botucatu
-
Sao Paulo, SP, Brazil, 05403-010
- Active, not recruiting
- Hospital das Clinicas - FMUSP
-
São Paulo, SP, Brazil, 01232-010
- Withdrawn
- Hospital Samaritano
-
-
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 1L8
- Recruiting
- Vancouver General Hospital
-
-
Ontario
-
Toronto, Ontario, Canada, M5B 1W8
- Recruiting
- St. Michael's Hospital
-
Toronto, Ontario, Canada, M5G 2C4
- Recruiting
- Toronto General Hospital
-
-
-
-
-
Beijing, China, 100034
- Recruiting
- Peking University First Hospital; NEPHROLOGY
-
Beijing City, China, 100045
- Recruiting
- Beijing Children's Hospital, Capital Medical University
-
-
-
-
-
Montpellier, France, 34295
- Recruiting
- Hopital Lapeyronie; Nephrologie
-
Montpellier, France, 34295
- Recruiting
- Hôpital Arnaud de Villeneuve; Néphrologie pédiatrique
-
Paris, France, 75019
- Recruiting
- Hôpital Robert Debré; Nephrologie pediatrique
-
Paris, France, 75743
- Recruiting
- Gh Necker Enfants Malades; Nephrologie
-
Paris, France, 75970
- Recruiting
- Hopital Tenon; Service SINRA
-
-
-
-
-
Essen, Germany, 45122
- Recruiting
- Universitätsklinikum Essen; Klinik für Kinder- und Jugendmedizin Pädiatrie II
-
Essen, Germany, 45147
- Recruiting
- Klinik für Nephrologie des Universitätsklinikum Essen; Klinik für Infektiologie - MFZ
-
Hannover, Germany, 30625
- Recruiting
- Medizinische Hochschule Hannover; Klinik für Nieren- und Hochdruckerkrankungen
-
Köln, Germany, 50937
- Recruiting
- Klinik II für Nephrologie, Rheumatologie, Diabetologie und Allgemeine Innere Medizin
-
-
-
-
-
Budapest, Hungary, 1097
- Recruiting
- Del- Pesti Centrumkorhaz- Szent Laszlo Korhaz Telephely
-
-
-
-
Delhi
-
New Delhi, Delhi, India, 110029
- Recruiting
- All India Institute of Medical Sciences (AIIMS)
-
-
Haryana
-
Gurgaon, Haryana, India, 122001
- Recruiting
- Medanta-The Medicity
-
-
Rajasthan
-
Jaipur, Rajasthan, India, 302004
- Recruiting
- Sawai Man Singh Hospital and Medical College
-
-
-
-
-
Haifa, Israel, 3109601
- Active, not recruiting
- Rambam Medical Center; Department of Nephrology and Hypertension
-
Petach Tikva, Israel, 0049100
- Recruiting
- Rabin Medical Center; Nephrology
-
Ramat-Gan, Israel, 5262000
- Recruiting
- Sheba MC; Nephrology
-
-
-
-
Lazio
-
Roma, Lazio, Italy, 00168
- Recruiting
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS; U.O.C. Nefrologia
-
-
Liguria
-
Genova, Liguria, Italy, 16132
- Recruiting
- A.O. Universitaria S. Martino Di Genova; Nefrologia
-
-
Lombardia
-
Milano, Lombardia, Italy, 20122
- Recruiting
- Presidio Ospedaliero Maggiore Policlinico Fondazione IRCCS; Pad Croff Div Nefrologia Dialisi
-
-
Toscana
-
Firenze, Toscana, Italy, 50139
- Recruiting
- Az. Osp. Careggi; Reparto Di Nefrologia, Dialisi E Trapianti
-
-
-
-
-
Aichi, Japan, 466-8560
- Recruiting
- Nagoya University Hospital
-
Mie, Japan, 514-8507
- Recruiting
- Mie University Hospital
-
Saitama, Japan, 350-0451
- Active, not recruiting
- Saitama Medical University Hospital
-
Tokyo, Japan, 113-8655
- Recruiting
- The University of Tokyo Hospital
-
-
-
-
Jalisco
-
Zapopan, Jalisco, Mexico, 45116
- Recruiting
- Hospital de Especialidades Puerta de Hierro S.A de C.V.
-
-
Mexico CITY (federal District)
-
Ciudad de México, Mexico CITY (federal District), Mexico, 14080
- Recruiting
- Instituto Nacional de Ciencias; Medicas y Nutricion; Salvador Zubiran
-
Distrito Federal, Mexico CITY (federal District), Mexico, 06726
- Active, not recruiting
- Hospital General de Mexico
-
-
Nuevo LEON
-
Monterrey, Nuevo LEON, Mexico, 64460
- Recruiting
- Hospital Universitario "Dr. Jose Eleuterio Gonzalez"
-
-
Sinaloa
-
Culiacán Rosales, Sinaloa, Mexico, 80230
- Withdrawn
- Centro para el Desarrollo de la Medicina y de Asistencia
-
-
-
-
-
Auckland, New Zealand, 1001
- Recruiting
- Auckland City Hospital; Renal Unit, Level 15
-
Christchurch, New Zealand, 8011
- Recruiting
- New Zealand Clinical Research - Christchurch
-
Dunedin, New Zealand, 9054
- Recruiting
- Dunedin Hospital; Otago District Health Board
-
-
-
-
-
Bellavista, Peru, Callao 2
- Recruiting
- Hospital IV Alberto Sabogal Sologuren; Unidad de Investigacion
-
Lima, Peru
- Recruiting
- Hospital Nacional Dos de Mayo
-
-
-
-
-
Gdansk, Poland, 80-952
- Recruiting
- Uniwersyteckie Centrum Kliniczne; Klinika Chorob Nerek i Nadci?nienia Dzieci i Mlodziezy
-
Lodz, Poland, 93-338
- Active, not recruiting
- Instytut ?Centrum Zdrowia Matki Polki; Klinika Pediatrii i Immunologii i Nefrologii
-
Warszawa, Poland, 02-097
- Recruiting
- SAMODZIELNY PUBLICZNY CENTRALNY SZPITAL KLINICZNY; Department KLINIKA NEFROLOGII, DIALIZOTERAPII I C
-
Zabrze, Poland, 41-800
- Recruiting
- Szpital Kliniczny nr 1 im. prof. Szyszko; Oddz. Nefrologii Dzieciecej z Pododdzia?em Dializoterapii
-
-
-
-
-
Rondebosch, South Africa, 7700
- Recruiting
- Red Cross War Memorial Children's Hospital; Pediatric Nephrology
-
Umkumbaan, South Africa, 4091
- Withdrawn
- Inkosi Albert Luthuli Central Hospital; Pediatric Nephrology
-
-
-
-
-
Barcelona, Spain, 08036
- Recruiting
- Hospital Clinic i Provincial; Servicio de Nefrologia
-
Madrid, Spain, 28041
- Recruiting
- Hospital Universitario 12 de Octubre; Servicio de Nefrologia
-
Sevilla, Spain, 41013
- Recruiting
- Hospital Universitario Virgen del Rocío
-
-
LA Coruña
-
La Coruna, LA Coruña, Spain, 15006
- Recruiting
- Complejo Hospitalario Universitario A Coruña (CHUAC); Servicio de Nefrologia
-
-
-
-
-
Istanbul, Turkey, 34390
- Recruiting
- Istanbul University Istanbul Medical Faculty; Department of Internal Medicine
-
Kayseri, Turkey, 38039
- Withdrawn
- Erciyes University Medical Faculty; Internal Medicine
-
Kocaeli, Turkey, 41380
- Active, not recruiting
- Kocaeli University Medical Faculty
-
Konya, Turkey, 42080
- Recruiting
- Necmettin Erbakan University Meram Medical Faculty ; Internal Diseases
-
Malatya, Turkey, 44280
- Withdrawn
- Inonu University Faculty of Medicine Turgut Ozal Medical Center
-
Malatya, Turkey, 44330
- Recruiting
- Malatya Park Hospital
-
Samsun, Turkey, 55139
- Withdrawn
- Ondokuz Mayis Univ. Med. Fac.
-
-
-
-
California
-
Orange, California, United States, 92868
- Recruiting
- University of California Irvine Chao Family Comprehensive Cancer Center
-
Sacramento, California, United States, 95817
- Recruiting
- University of California Davis
-
San Francisco, California, United States, 94143-0435
- Recruiting
- Univ of CA San Francisco
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Recruiting
- Children's Hospital Colorado
-
-
Florida
-
Hollywood, Florida, United States, 33021
- Recruiting
- Memorial Healthcare Systems
-
-
Georgia
-
Atlanta, Georgia, United States, 20010
- Recruiting
- Emory Children's Center
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Recruiting
- Brigham and Womens Hospital
-
-
Missouri
-
Saint Louis, Missouri, United States, 63128
- Recruiting
- Washington University
-
-
New York
-
Stony Brook, New York, United States, 11790
- Recruiting
- SUNY At Stony Brook
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229
- Recruiting
- Cincinnati Children's Hospital Medical Center
-
Columbus, Ohio, United States, 43212
- Recruiting
- The Ohio State University Wexner Medical Center
-
-
Texas
-
San Antonio, Texas, United States, 78229
- Active, not recruiting
- UT Health Science Center; SouthTexas Pediatric Blood and Cancer Ctr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Body weight >= 40 kg at screening.
- Vaccination against Neisseria meningitidis serotypes A, C, W, and Y; vaccination against serotypes B, according to national vaccination recommendations.
- Vaccination against Haemophilus influenzae type B and Streptococcus pneumoniae, according to national vaccination recommendations.
- For participants continuing to receive other therapies concomitantly with crovalimab (e.g., immunosuppressants, corticosteroids, mammalian target of rapamycin inhibitor (mTORi) , or calcineurin inhibitors): stable dose for >=28 days prior to screening and up to the first crovalimab administration.
- For female participants of childbearing potential: an agreement to remain abstinent or use contraception.
- Female participants of childbearing potential must have a negative serum pregnancy test result within 7 days prior to initiation of crovalimab.
- Participants with a prior kidney transplant are eligible if they have a known history of complement-mediated aHUS prior to the kidney transplant.
- Onset of initial TMA presentation within 28 days prior to the first dose of crovalimab (for Naive Cohort only).
- Documented treatment with either eculizumab or ravulizumab (for Switch Cohort only).
- Clinical evidence of response to a C5 inhibitor (for Switch Cohort only).
- Known C5 polymorphism (for C5 SNP Cohort only).
- Poorly controlled TMA following treatment with another C5 inhibitor (for C5 SNP Cohort only).
Exclusion Criteria:
- TMA associated with non-aHUS related renal disease.
- Positive direct Coombs test.
- Chronic dialysis within 90 days prior to first crovalimab administration and/or end stage renal disease.
- Identified drug exposure-related TMA.
- Presence or history of a condition that could trigger TMA, such as malignancy, bone marrow or organ transplant (other than kidney transplant) or autoimmune disease.
- History of a kidney disease, other than aHUS.
- History of Neisseria meningitidis infection within 6 months of study enrollment.
- Known or suspected immune deficiency (e.g., history of frequent recurrent infections).
- Positive Human Immunodeficiency Virus (HIV) test.
- Active systemic bacterial, viral, or fungal infection within 14 days before first crovalimab administration
- Presence of fever (>= 38°C ) within 7 days before the first crovalimab administration
- Multi-system organ dysfunction or failure.
- Recent intravenous immunoglobulin (IVIg) treatment.
- Pregnant or breastfeeding or intending to become pregnant.
- Participation in another interventional treatment study with an investigational agent or use of any experimental therapy within 28 days of screening or within five half lives of that investigational product, whichever is greater.
- Recent use of tranexamic acid.
- Current or previous treatment with a complement inhibitor (for Naive Cohort only).
- First initiation of plasma exchange/plasma infusions (PE/PI) should not be more than 28 days prior to first crovalimab administration (for Naive Cohort only).
- Last PE/PI completed less than 2 hours prior to first crovalimab administration (for Naive Chorot only).
- Receiving PE/PI within 8 weeks of the first crovalimab administration (Switch Cohort only).
- Positive for active Hepatitis B and C infection (HBV/HCV) (for Switch Cohort and C5 SNP Cohort participants who recently received C5 inhibitor treatment).
- Cryoglobulinemia at screening (for Switch Cohort and C5 SNP Cohort participants who recently received C5 inhibitor treatment).
- Documented condition leading to non-aHUS TMA: Thrombotic Thrombocytopenic Purpura (TTP), Shiga Toxin producing Escherichia Coli (STEC)
- TMA, Pneumococcal HUS, TMA secondary to cobalamin C defect and TMA related to a known DGKE nephropathy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Crovalimab
Participants will be enrolled in three cohorts: [1] Naive Cohort - participants who have not been previously treated with complement inhibitor therapy; [2] Switch Cohort - participants who switch to crovalimab from another C5 inhibitor and [3] C5 SNP (Single Nucleotide Polymorphism) Cohort - participants with documented C5 polymorphism.
|
Crovalimab will be administered at a dose of 1000 mg IV (for participants with body weight between 40 and 100kg) or 1500 mg IV (for participants with body weight >=100kg) on Week 1 Day 1.
On Week 1 Day 2 and on Weeks 2, 3 and 4, it will be administered at a dose of 340 mg SC.
On Week 5 and Q4W thereafter, it will be administered at a dose of 680 mg SC (for participants with body weight between 40 and 100kg) or 1020 mg SC (for participants with body weight >=100kg).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percentage of Participants with complete TMA response (cTMAr)
Time Frame: Baseline up to Week 25
|
Baseline up to Week 25
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants with Platelet Count >= Lower Limits of Normal (LLN) (Naive Cohort only)
Time Frame: Baseline up to Week 25
|
Baseline up to Week 25
|
|
Percentage of Participants with Normalization of LDH (i.e. =< Upper Limit of Normal (ULN)) (Naive Cohort only)
Time Frame: Baseline up to Week 25
|
Baseline up to Week 25
|
|
Percentage of Participants with >=25% decrease in Serum Creatinine (Naive Cohort only)
Time Frame: Baseline up to Week 25
|
Baseline up to Week 25
|
|
Percentage of Participants with complete TMA response (cTMAr) (Naive Cohort only)
Time Frame: Week 25
|
Week 25
|
|
Percentage of Participants with maintained TMA control (mTMAc) (Switch Cohort only)
Time Frame: Baseline through Week 25
|
Baseline through Week 25
|
|
Change from Baseline in Dialysis Status
Time Frame: Baseline up to Week 25
|
Baseline up to Week 25
|
|
Change from Baseline in Estimated Glomerular Filtration Rate (eGFR)
Time Frame: Baseline up to Week 25
|
Baseline up to Week 25
|
|
Percentage of Participants with Change from Baseline in Chronic Kidney Disease (CKD) stage
Time Frame: Baseline up to Week 25
|
Baseline up to Week 25
|
|
Observed Value in Platelet Count
Time Frame: Baseline up to Week 25
|
Baseline up to Week 25
|
|
Observed Value in Lactate Dehydrogenase (LDH)
Time Frame: Baseline up to Week 25
|
Baseline up to Week 25
|
|
Observed Value in Hemoglobin
Time Frame: Baseline up to Week 25
|
Baseline up to Week 25
|
|
Change from Baseline in Platelet Count
Time Frame: Baseline up to Week 25
|
Baseline up to Week 25
|
|
Change from Baseline in Lactate Dehydrogenase (LDH)
Time Frame: Baseline up to Week 25
|
Baseline up to Week 25
|
|
Change from Baseline in Hemoglobin
Time Frame: Baseline up to Week 25
|
Baseline up to Week 25
|
|
Mean Change From Baseline in Fatigue (in Adult Participants only)
Time Frame: Baseline up to Week 25
|
Assessed by the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Questionnaire. The FACIT-Fatigue (version 4) assesses self-reported fatigue and its impact upon daily activities and function. It consists of 13 items that assess fatigue using a 7-day recall period. Items are scored on a 0 (not at all) to 4 (very much) response scale. Relevant items are reverse scored and all items are summed to create total scores ranging from 0 [worse score] to 52 [better score]. |
Baseline up to Week 25
|
Time to complete TMA response (cTMAr) (Naive Cohort only)
Time Frame: Up to 9 years
|
Up to 9 years
|
|
Duration of complete TMA response (cTMAr) (Naive Cohort only)
Time Frame: Up to 9 years
|
Up to 9 years
|
|
Percentage of Participants with Adverse Events (AEs)
Time Frame: Up to 9 years
|
Up to 9 years
|
|
Percentage of Participants with Injection-Site Reactions, Infusion-Related Reactions, Hypersensitivity, Malignant Hypertension (including malignant renal hypertension) and Infections (including meningococcal meningitis)
Time Frame: Up to 9 years
|
Up to 9 years
|
|
Percentage of Participants with Adverse Events (AEs) leading to Study Drug Discontinuation
Time Frame: Up to 9 years
|
Up to 9 years
|
|
Percentage of Participants with Clinical Manifestations of Drug-Target-Drug Complex (DTDC) Formation Amongst Those Participants who Switched to Crovalimab Treatment From Eculizumab Treatment or Ravulizumab Treatment
Time Frame: Up to Week 25
|
Up to Week 25
|
|
Serum Concentrations of Crovalimab Over Time
Time Frame: Up to 9 years
|
Up to 9 years
|
|
Percentage of Participants with Anti-Crovalimab Antibodies
Time Frame: Up to 9 years
|
Up to 9 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Clinical Trials, Hoffmann-La Roche
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Kidney Diseases
- Urologic Diseases
- Disease
- Hematologic Diseases
- Anemia
- Thrombocytopenia
- Blood Platelet Disorders
- Anemia, Hemolytic
- Thrombotic Microangiopathies
- Uremia
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Cytopenia
- Syndrome
- Azotemia
- Hemolysis
- Hemolytic-Uremic Syndrome
- Atypical Hemolytic Uremic Syndrome
Other Study ID Numbers
- BO42353
- 2020-002475-35 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atypical Hemolytic Uremic Syndrome
-
AlexionCompletedAtypical Hemolytic-Uremic SyndromeUnited Kingdom, United States, France, Italy, Germany, Spain, Belgium
-
Alexion PharmaceuticalsCompletedAtypical Hemolytic-Uremic SyndromeUnited Kingdom, Belgium, United States, Germany, Italy, France, Netherlands, Australia, Canada
-
University Hospital, ToursHospices Civils de Lyon; University Hospital, Strasbourg, France; University... and other collaboratorsActive, not recruitingHemolytic-Uremic Syndrome, AtypicalFrance
-
AlexionSyneos HealthRecruitingAtypical Hemolytic-Uremic SyndromeFrance, Germany, Israel, Italy, United Kingdom, Canada, United States, Australia, Belgium, Denmark, Korea, Republic of, Poland, Russian Federation, Spain, Taiwan
-
Alexion PharmaceuticalsCompletedAtypical Hemolytic Uremic Syndrome (aHUS)Japan
-
Alexion PharmaceuticalsCompletedATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS)Japan
-
Maastricht University Medical CenterRecruitingThrombotic Microangiopathies | Hemolytic-Uremic Syndrome | Hemolytic Uremic Syndrome, AtypicalNetherlands
-
University Hospital, GhentCompletedAtypical Hemolytic Uraemic SyndromeBelgium
-
AstraZenecaRecruitingAtypical Hemolytic Uremic Syndrome(aHUS)China
-
Alexion Pharmaceuticals, Inc.CompletedAtypical Hemolytic Uremic Syndrome (aHUS)United States, France, Spain, Taiwan, United Kingdom, Australia, Belgium, Germany, Italy, Japan, Korea, Republic of, Russian Federation, Austria, Canada
Clinical Trials on Crovalimab
-
Hoffmann-La RocheRecruitingSickle Cell DiseaseUnited States, Spain, Brazil, United Kingdom, Italy, Turkey, Kenya, Netherlands, France, South Africa, Lebanon
-
Hoffmann-La RocheRecruitingSickle Cell DiseaseUnited States, Brazil, Italy, Spain, Kenya, Netherlands, United Kingdom, France, South Africa
-
Hoffmann-La RocheActive, not recruiting
-
Hoffmann-La RocheChugai PharmaceuticalRecruitingAtypical Hemolytic Uremic SyndromeUnited States, Belgium, China, France, Spain, Canada, South Africa, Japan, Brazil, Italy, Poland, India, Hungary, Mexico, Israel
-
Hoffmann-La RocheChugai PharmaceuticalActive, not recruitingParoxysmal Hemoglobinuria, NocturnalFrance, Korea, Republic of, Italy, Japan, Germany, Hungary, Netherlands
-
Hoffmann-La RocheChugai PharmaceuticalActive, not recruitingParoxysmal Nocturnal HemoglobinuriaSpain, Korea, Republic of, France, Sweden, Thailand, Malaysia, China, Turkey, Netherlands, Japan, Australia, United Kingdom, Germany, Brazil, Romania, Argentina, Poland, Greece, Hong Kong, Lithuania, Mexico, Philippines, Portugal, Sin... and more
-
Hoffmann-La RocheChugai PharmaceuticalRecruitingParoxysmal Nocturnal HemoglobinuriaUnited States, Korea, Republic of, Spain, Germany, Italy, Sweden, Netherlands, Japan, Belgium, Greece, Colombia, Saudi Arabia, Turkey, Poland, Ireland, Brazil, Canada, Czechia, Estonia, France, Hong Kong, Singapore, Taiwan, United Kingdom and more
-
Hoffmann-La RocheChugai Pharmaceutical Co., Ltd. (Sponsor in Taiwan and Japan)Withdrawn